Amitabh Chandra
Amitabh Chandra
Amitabh Chandra is a renowned economist, professor, and researcher who has made significant contributions to the field of health economics. He is currently the McCance Family Professor of Business Administration at Harvard Business School and Director of Health Policy Research at the Harvard Kennedy School of Government. He is also a member of the Congressional Budget Office's Panel of Health Advisors and a Research Associate at the National Bureau of Economic Research (NBER).
With a Doctor of Philosophy (PhD) degree in Economics from the University of Kentucky, Chandra has focused his research on innovation in health care, finance in healthcare, productivity and cost-growth in healthcare, medical malpractice, and racial disparities in health care. He has published his research in various prestigious academic journals, such as the American Economic Review, the Journal of Political Economy, and the New England Journal of Medicine.
Chandra has testified to the United States Senate and the United States Commission on Civil Rights, and his research has been featured in the New York Times, the Washington Post, CNN, Newsweek, and on National Public Radio. In 2011, he served as Massachusetts' Special Commissioner on Provider Price Reform.
As an elected member of the Institute of Medicine, Chandra has also received numerous awards for his work, including the Upjohn Institute's Dissertation Award, the Kenneth Arrow Award for best paper in health economics, and the Eugene Garfield Award for the impact of medical research. In 2012, he was awarded the American Society of Health Economists (ASHE) medal, given biennially to the economist age 40 or under who has made the most significant contributions to the field of health economics.
Overall, Professor Chandra's impressive credentials, extensive research experience, and noteworthy contributions to the field of health economics make him a well-respected and renowned figure in his field.
@daviesbj Did you and @AnupamBJena get a 2-for-1 deal on those shoes?
RT @nberpubs: While FDA review is often described as increasing costs and perhaps slowing flow of new products, by certifying quality, this…